title: Clinical Efficacy of Therapy with Recombinant Human Interferon α1b in Hand, Foot, and Mouth Disease with Enterovirus 71 Infection.
abstract: A rapid expansion of HFMD with enterovirus 71 infection outbreaks has occurred and caused deaths in recent years in China, but no vaccine or antiviral drug is currently available for EV71 infection. This study aims to provide treatment programs for HFMD patients. We conducted a randomized, double-blind, controlled trial and evaluated clinical efficacy of therapy with rHuIFN-α1b in HFMD patients with EV71 infection. There were statistical differences in outcomes including the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load of the HFMD patients among ultrasonic aerosol inhalation group, intramuscular injection group and control group. rHuIFN-α1b therapy reduced the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load in children with HFMD.
  
  
  BACKGROUND
  Chinese Clinical Trial Registry ChiCTR-TRC-14005153.
authors.affiliation: Henan Center for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Xueyong
authors.initials: X
authors.lastname: Huang
authors.affiliation: Children's Hospital of Kaifeng City, Zhengzhou, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Children's Hospital of Zhengzhou City, Zhengzhou, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.affiliation: Henan Center for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Wei
authors.affiliation: Henan Center for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Ma
authors.affiliation: College of Public Health, Zhengzhou University, Zhengzhou, China.
authors.forename: Meili
authors.initials: M
authors.lastname: Sui
authors.affiliation: College of Public Health, Zhengzhou University, Zhengzhou, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Lu
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Huaili
authors.initials: H
authors.lastname: Wang
authors.affiliation: Departments of Pathology and Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
authors.forename: J Stephen
authors.initials: JS
authors.lastname: Dumler
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
authors.forename: Guangyao
authors.initials: G
authors.lastname: Sheng
authors.affiliation: Henan Center for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Bianli
authors.initials: B
authors.lastname: Xu
mesh_terms: D002675:Child, Preschool; D002681:China; D004311:Double-Blind Method; D029821:Enterovirus A, Human / Q000187:drug effects / Q000472:pathogenicity; D004769:Enterovirus Infections / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000821:virology; D005260:Female; D006232:Hand, Foot and Mouth Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000821:virology; D006801:Humans; D007223:Infant; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000235:genetics; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D011994:Recombinant Proteins